Literature DB >> 2418147

Characterization of a monoclonal antibody directed against the biologically active site of human interleukin 1.

A Köck, M Danner, B M Stadler, T A Luger.   

Abstract

Human IL-1 was successfully used to produce an anti-IL-1 mAb. Anti-IL-1 (IgG2a) blocked IL-1-mediated thymocyte and fibroblast proliferation, but did not interfere with the biological effects of other lymphokines, such as IL-2 or IL-3. The antibody immunoprecipitated biosynthetically radiolabeled 33, 17, and 4 kD IL-1. An immunoadsorbent column yielded 20% of initial activity, and upon HPLC size-exclusion chromatography, affinity-purified IL-1 had a molecular mass of approximately 4 kD. These results provide first evidence of a monoclonal anti-IL-1 that reacts with different species of IL-1 and apparently binds to an epitope close to the active site of IL-1. Thus, anti-IL-1 IgG may be very helpful for further investigations of the molecular as well as biological characteristics of IL-1 and related mediators.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418147      PMCID: PMC2188039          DOI: 10.1084/jem.163.2.463

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  A dot-immunobinding assay for monoclonal and other antibodies.

Authors:  R Hawkes; E Niday; J Gordon
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

3.  The biochemical and biological characterization of lymphocyte regulatory molecules. VI. Generation of a B cell hybridoma whose antibody product inhibits interleukin 2 activity.

Authors:  S Gillis; C S Henney
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

4.  Interleukin 1 activity in normal human urine.

Authors:  E S Kimball; S F Pickeral; J J Oppenheim; J L Rossio
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

5.  Characteristics of an epidermal cell thymocyte-activating factor (ETAF) produced by human epidermal cells and a human squamous cell carcinoma cell line.

Authors:  T A Luger; B M Stadler; B M Luger; M B Sztein; J A Schmidt; P Hawley-Nelson; G Grabner; J J Oppenheim
Journal:  J Invest Dermatol       Date:  1983-09       Impact factor: 8.551

6.  Purification of human interleukin 1 by high-performance liquid chromatography.

Authors:  A Köck; T A Luger
Journal:  J Chromatogr       Date:  1984-07-27

7.  Preparation of goat antibodies against interleukin 1: use of an immunoadsorbent to purify interleukin 1.

Authors:  S B Mizel; M Dukovich; J Rothstein
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

8.  Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture.

Authors:  T A Luger; J S Smolen; T M Chused; A D Steinberg; J J Oppenheim
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

9.  Cloning and expression of murine interleukin-1 cDNA in Escherichia coli.

Authors:  P T Lomedico; U Gubler; C P Hellmann; M Dukovich; J G Giri; Y C Pan; K Collier; R Semionow; A O Chua; S B Mizel
Journal:  Nature       Date:  1984 Nov 29-Dec 5       Impact factor: 49.962

10.  Biosynthesis and transport of cathepsin D in cultured human fibroblasts.

Authors:  V Gieselmann; R Pohlmann; A Hasilik; K Von Figura
Journal:  J Cell Biol       Date:  1983-07       Impact factor: 10.539

View more
  2 in total

1.  Defective intralesional interferon-gamma activity in patients with lepromatous leprosy.

Authors:  B Volc-Platzer; H Stemberger; T Luger; T Radaszkiewicz; G Wiedermann
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

2.  Characterization and specificity of a high titre polyclonal goat anti-murine IL-1 antibody.

Authors:  M E Scheetz; D G Carlson; J L Bobbitt; L D Butler; S H Zuckerman
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.